Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time

@article{Dhondt2018DiscoveryAV,
  title={Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time},
  author={Bert Dhondt and Elise De Bleser and Tom Claeys and Sarah Buelens and Nicolaas Lumen and Jo Vandesompele and Anneleen Beckers and Val{\'e}rie Fonteyne and Kim Van der Eecken and Aur{\'e}lie De Bruycker and J{\'e}r{\^o}me Paul and Pierre Gramme and Piet Ost},
  journal={World Journal of Urology},
  year={2018},
  pages={1-8}
}
PurposePatients with oligometastatic prostate cancer (PC) may benefit from metastasis-directed therapy (MDT), delaying disease progression and the start of palliative systemic treatment. However, a significant proportion of oligometastatic PC patients progress to polymetastatic PC within a year following MDT, suggesting an underestimation of the metastatic load by current staging modalities. Molecular markers could help to identify true oligometastatic patients eligible for MDT.MethodsPatients… 

Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review

The aim of the present narrative review is to report the current state of the art on the solidity of liquid biopsy-related analytes such as CTCs, cfDNA, miRNA and epi-miRNA and their reliability as biomarkers in the clinics for the identification of true-oligometastatic patients and to provide a benchmark for their further clinical implementation.

Progression-free survival in patients with 68Ga-PSMA-PET-directed SBRT for lymph node oligometastases

A median PFS of 16 months was attained after SBRT for patients with PSMA-PET positive oligometastatic lymph nodes from prostate cancer, and higher pre-SBRT PSA, younger age and extrapelvic location were found to be predictors of shorter PFS.

Prognostic and Predictive Biomarkers in Oligometastatic Disease

Prognostic and predictive biomarkers of oligometastatic disease are strongly needed to identify patient candidates most likely to gain survival benefit from local therapies and to aid in the incorporation of ablative treatments in the context of existing systemic therapies.

Molecular Mechanisms Related with Oligometastatic Prostate Cancer—Is It Just a Matter of Numbers?

The current narrative review provides an overview of the current treatment landscape of oligometastatic cancer, focusing on the current biomarkers used in the identification of true oligometricastatic disease and highlighting the impact of molecular imaging on stage shift in different scenarios.

Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer

Oligo-MBC defined as MBC limited to 1-3 metastases was associated with favorable OS and progression-free survival in OMBC, independent of local therapy of the primary tumor.

Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries

Most trials address local ablative treatments both for prostate and/or metastases, typically by radiotherapy, and several attempts to determine the benefit of adding systemic therapy.

Known epigenetic biomarkers for prostate cancer detection and management: exploring the potential of blood-based liquid biopsies

An overview of epigenetic biomarkers current state is provided based on a comprehensive review of the relevant literature in blood-based liquid biopsies and challenges/limitations of this new and growing field of cancer biomarkers.

The Road to Dissemination: The Concept of Oligometastases and the Barriers for Widespread Disease

The route to dissemination is explored: the hurdles a tumoral clone has to overtake before it can produce efficient and widespread dissemination, and selective dissemination is illustrated by discussing organ tropism, the preference of different cancer (sub)types to metastasize to certain organs.

Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document Radiotherapy and Oncology

Consensus was reached that OMD is largely independent of primary tumour, metastatic loca- tion and the presence or length of a disease-free interval, supporting both synchronous and metachronous OMD.

References

SHOWING 1-10 OF 32 REFERENCES

MicroRNA Expression Characterizes Oligometastasis(es)

Background Cancer staging and treatment presumes a division into localized or metastatic disease. We proposed an intermediate state defined by ≤5 cumulative metastasis(es), termed oligometastases. In

Oligo- and Polymetastatic Progression in Lung Metastasis(es) Patients Is Associated with Specific MicroRNAs

Oligo- and poly- metastasis are distinct entities at the clinical and molecular level and prioritized microRNAs distinguished HRP from LRP and were associated with rate of metastatic progression and survival in an independent validation dataset.

Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology

Current developments in molecular imaging have allowed for improved detection of metastatic prostate cancer allowing for more accurate staging of patients with oligometastatic disease and future development of biologic markers may assist in defining the oligometricastatic state and determining prognosis.

Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis

Three integrated molecular subtypes of colorectal cancer liver metastasis are identified, which complement clinical risk stratification to distinguish the subset of oligometastatic patients and provide a framework for integrated classification and treatment of metastasis.

Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.

ADT-free survival was longer with MDT than with surveillance alone for oligorecurrent PCa, suggesting that MDT should be explored further in phase III trials.

Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer

Purpose of review To summarize the available literature regarding radiotherapy as a metastasis-directed therapy (MDT) in the treatment of oligometastatic prostate cancer (PCa). Recent findings Three

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)

The ORIOLE trial is the first randomized, non-blinded Phase II interventional study in the North America evaluating the safety and efficacy of SABR in oligometastatic hormone-sensitive prostate cancer and leading-edge laboratory and imaging correlates will provide unique insight into the effects of S ABR on the oligometricastatic state.

Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial.